Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (504) 504
Publication (64) 64
Book Review (6) 6
Book Chapter (3) 3
Book / eBook (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Patent (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (323) 323
female (299) 299
oncology (272) 272
breast cancer (210) 210
breast neoplasms - drug therapy (181) 181
middle aged (181) 181
adult (159) 159
index medicus (155) 155
aged (137) 137
chemotherapy (128) 128
breast neoplasms - pathology (126) 126
chemotherapy, adjuvant (104) 104
cancer (97) 97
antineoplastic combined chemotherapy protocols - therapeutic use (94) 94
prognosis (86) 86
disease-free survival (83) 83
treatment outcome (82) 82
therapy (81) 81
breast neoplasms - mortality (71) 71
tamoxifen (69) 69
breast neoplasms - surgery (63) 63
hematology, oncology and palliative medicine (62) 62
antineoplastic agents, hormonal - therapeutic use (58) 58
breast neoplasms - therapy (53) 53
care and treatment (53) 53
clinical trials (52) 52
breast neoplasms - metabolism (48) 48
tamoxifen - therapeutic use (46) 46
lymphatic metastasis (45) 45
neoplasm staging (45) 45
postmenopausal women (45) 45
research (45) 45
survival (42) 42
follow-up studies (41) 41
women (41) 41
adjuvant treatment (39) 39
medicine & public health (38) 38
aged, 80 and over (37) 37
combined modality therapy (36) 36
cyclophosphamide - administration & dosage (36) 36
estrogen (36) 36
medicine, general & internal (36) 36
receptors, estrogen - metabolism (36) 36
cyclophosphamide (35) 35
drug therapy (35) 35
fluorouracil - administration & dosage (35) 35
survival analysis (35) 35
health aspects (34) 34
surgery (34) 34
trastuzumab (34) 34
retrospective studies (33) 33
risk factors (33) 33
analysis (32) 32
carcinoma (32) 32
endocrine therapy (32) 32
obstetrics & gynecology (32) 32
quality of life (32) 32
article (31) 31
drug administration schedule (31) 31
postmenopause (31) 31
adjuvant chemotherapy (30) 30
antineoplastic agents - therapeutic use (30) 30
male (30) 30
mastectomy (30) 30
antineoplastic combined chemotherapy protocols - administration & dosage (29) 29
cancer patients (29) 29
randomized controlled trials as topic (29) 29
receptor, erbb-2 - metabolism (29) 29
receptors, estrogen - analysis (29) 29
antineoplastic combined chemotherapy protocols - adverse effects (28) 28
randomized-trial (28) 28
survival rate (28) 28
tamoxifen - administration & dosage (28) 28
breast neoplasms - genetics (26) 26
immunohistochemistry (26) 26
methotrexate - administration & dosage (26) 26
clinical trials as topic (25) 25
oncology, experimental (25) 25
premenopause (25) 25
proportional hazards models (25) 25
kaplan-meier estimate (24) 24
menopause (24) 24
antineoplastic agents, hormonal - adverse effects (23) 23
breast neoplasms - chemistry (23) 23
methotrexate (23) 23
trial (23) 23
tumors (23) 23
cancer therapies (22) 22
tamoxifen - adverse effects (21) 21
antineoplastic agents - adverse effects (20) 20
receptors, progesterone - metabolism (20) 20
nitriles - therapeutic use (19) 19
radiotherapy (19) 19
triazoles - therapeutic use (19) 19
adjuvant therapy (18) 18
antineoplastic agents (18) 18
breast neoplasms (18) 18
fluorouracil (18) 18
letrozole (18) 18
metastasis (18) 18
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Interview with Dr Aron Goldhirsch
by Goldhirsch, A
EUROPEAN JOURNAL OF CANCER, ISSN 0959-8049, 09/2002, Volume 38, Issue 14, pp. 1814 - 1814
ONCOLOGY | Career Mobility | Medical Oncology | Female | Research | Breast Neoplasms | Humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
by Cameron, David, Prof and Piccart-Gebhart, Martine J, PhD and Gelber, Richard D, PhD and Procter, Marion, PhD and Goldhirsch, Aron, MD and de Azambuja, Evandro, MD and Castro, Gilberto, MD and Untch, Michael, MD and Smith, Ian, MD and Gianni, Luca, MD and Baselga, Jose, MD and Al-Sakaff, Nedal, PhD and Lauer, Sabine, PhD and McFadden, Eleanor, MA and Leyland-Jones, Brian, MBBS and Bell, Richard, MBBS and Dowsett, Mitch, PhD and Jackisch, Christian, MD and Herceptin Adjuvant HERA Trial and Herceptin Adjuvant (HERA) Trial Study Team
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Summary Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall... 
Internal Medicine | SYSTEM | MEDICINE, GENERAL & INTERNAL | MULTICENTER | PHASE-3 TRIAL | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | PERTUZUMAB | Antineoplastic Agents, Immunological - administration & dosage | Trastuzumab - therapeutic use | Drug Administration Schedule | Follow-Up Studies | Biomarkers, Tumor - analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Antineoplastic Agents, Immunological - adverse effects | Breast Neoplasms - chemistry | Antineoplastic Agents, Immunological - therapeutic use | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Adult | Female | Aged | Receptor, ErbB-2 - analysis | Heart Diseases - chemically induced | Antimitotic agents | Medical colleges | Analysis | Adjuvant treatment | Monoclonal antibodies | Breast cancer | Antineoplastic agents | Cancer | Heart | Laboratories | Toxicity | Medical services | Clinical trials | Cancer therapies | Incidence | Motivation | Failure analysis | Surgery | Heart diseases | Recombinant | Medical research | Health risks | Mammography | Radiation therapy | Patients | Survival | ErbB-2 protein | Chemotherapy | Breast | Informed consent | Trastuzumab | Schedules | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial
by Galimberti, Viviana, Dr and Cole, Bernard F, PhD and Zurrida, Stefano, MD and Viale, Giuseppe, MD and Luini, Alberto, MD and Veronesi, Paolo, MD and Baratella, Paola, MD and Chifu, Camelia, MD and Sargenti, Manuela, MD and Intra, Mattia, MD and Gentilini, Oreste, MD and Mastropasqua, Mauro G, MD and Mazzarol, Giovanni, MD and Massarut, Samuele, MD and Garbay, Jean-Rémi, MD and Zgajnar, Janez, MD and Galatius, Hanne, MD and Recalcati, Angelo, MD and Littlejohn, David, FRACS and Bamert, Monika, MD and Colleoni, Marco, MD and Price, Karen N, BS and Regan, Meredith M, SD and Goldhirsch, Aron, MD and Coates, Alan S, MD and Gelber, Richard D, PhD and Veronesi, Umberto, MD and Int Breast Canc Study Grp Trial 23 and International Breast Cancer Study Group Trial 23-01 investigators
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 4, pp. 297 - 305
Summary Background For patients with breast cancer and metastases in the sentinel nodes, axillary dissection has been standard treatment. However, for patients... 
Hematology, Oncology and Palliative Medicine | INTERNATIONAL EXPERT CONSENSUS | PRIMARY THERAPY | ONCOLOGY | LYMPH-NODES | BIOPSY | METASTASES | INVOLVEMENT | AMERICAN-COLLEGE | HIGHLIGHTS | RECURRENCE | EARLY BREAST-CANCER | Breast Neoplasms - surgery | Lymph Nodes - pathology | Follow-Up Studies | Lymph Nodes - surgery | Humans | Middle Aged | Treatment Outcome | Lymphatic Metastasis | Breast Neoplasms - physiopathology | Disease-Free Survival | Neoplasm Grading | Neoplasm Micrometastasis | Breast Neoplasms - pathology | Axilla | Adult | Female | Aged | Sentinel Lymph Node Biopsy | Surgery
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
by Baselga, José, Dr and Bradbury, Ian, PhD and Eidtmann, Holger, MD and Di Cosimo, Serena, MD and de Azambuja, Evandro, MD and Aura, Claudia, MD and Gómez, Henry, MD and Dinh, Phuong, MD and Fauria, Karine, PhD and Van Dooren, Veerle, MSc and Aktan, Gursel, MD and Goldhirsch, Aron, MD and Chang, Tsai-Wang, MD and Horváth, Zsolt, MD and Coccia-Portugal, Maria, MD and Domont, Julien, MD and Tseng, Ling-Min, MD and Kunz, Georg, MD and Sohn, Joo Hyuk, MD and Semiglazov, Vladimir, MD and Lerzo, Guillermo, MD and Palacova, Marketa, MD and Probachai, Volodymyr, MD and Pusztai, Lajos, DPhil and Untch, Michael, PhD and Gelber, Richard D, PhD and Piccart-Gebhart, Martine, PhD and NeoALTTO Study Team and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Institute of Clinical Sciences, Section for Surgery and Gastrosurgical Research and Education, Department of Surgery and Institutionen för kliniska vetenskaper, sektionen för kirurgi och kirurgisk gastroforskning, Avdelningen för kirurgi and Sahlgrenska Academy
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
by Goldhirsch, Aron, Prof and Gelber, Richard D, Prof and Piccart-Gebhart, Martine J, Prof and de Azambuja, Evandro, MD and Procter, Marion, MSci and Suter, Thomas M, Prof and Jackisch, Christian, Prof and Cameron, David, Prof and Weber, Harald A, MD and Heinzmann, Dominik, PhD and Lago, Lissandra Dal, MD and McFadden, Eleanor, MA and Dowsett, Mitch, Prof and Untch, Michael, Prof and Gianni, Luca, MD and Bell, Richard, Prof and Köhne, Claus-Henning, Prof and Vindevoghel, Anita, MD and Andersson, Michael, MD and Brunt, A Murray, MD and Otero-Reyes, Douglas, MD and Song, Santai, MD and Smith, Ian, Prof and Leyland-Jones, Brian, PhD and Baselga, Jose, Prof and Herceptin Adjuvant HERA Trial and Herceptin Adjuvant (HERA) Trial Study Team
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9897, pp. 1021 - 1028
Summary Background Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | FOLLOW-UP | NSABP B-31 | THERAPY | CHEMOTHERAPY | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Follow-Up Studies | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Treatment Outcome | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Medication Adherence | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Aged | Chemotherapy, Adjuvant | Trastuzumab | Drug therapy | Breast cancer | Research | Chemotherapy | Radiation therapy | Cancer therapies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
by Gianni, Luca, Prof and Dafni, Urania, Prof and Gelber, Richard D, Prof and Azambuja, Evandro, PhD and Muehlbauer, Susanne, PhD and Goldhirsch, Aron, Prof and Untch, Michael, Prof and Smith, Ian, Prof and Baselga, José, Prof and Jackisch, Christian, Prof and Cameron, David, Prof and Mano, Max, MD and Pedrini, José Luiz, MD and Veronesi, Andrea, Prof and Mendiola, Cesar, MD and Pluzanska, Anna, Prof and Semiglazov, Vladimir, MD and Vrdoljak, Eduard, MD and Eckart, Michael J, MD and Shen, Zhenzhou, Prof and Skiadopoulos, George, MSci and Procter, Marion, MSci and Pritchard, Kathleen I, MD and Piccart-Gebhart, Martine J, PhD and Bell, Richard, MBBS and Herceptin Adjuvant HERA Trial Stud and Herceptin Adjuvant (HERA) Trial Study Team
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 3, pp. 236 - 244
Summary Background Treatment with adjuvant trastuzumab for 1 year improves disease-free survival and overall survival in patients with human epidermal growth... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | ONCOGENE | EFFICACY | ONCOLOGY | SAFETY | CLINICAL-TRIALS | PHASE-II | ANTIBODY | OVARIAN-CANCER | PLUS | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Randomized Controlled Trials as Topic | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized | Breast Neoplasms - pathology | Survival Analysis | Adult | Female | Receptor, ErbB-2 | Chemotherapy, Adjuvant | Trastuzumab | Antimitotic agents | Care and treatment | Epidermal growth factor | Adjuvant treatment | Breast cancer | Antineoplastic agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Endocrine therapy of breast cancer IV
by Goldhirsch, A
1990, Monographs / European School of Oncology., ISBN 9780387529615, 97
Hormone therapy | Breast | Cancer
Book
Details down arrow
8. Full Text Personalized adjuvant therapies: Lessons from the past
by Goldhirsch, Aron
Breast, The, ISSN 0960-9776, 2013, Volume 22, pp. S3 - S7
Abstract For several decades, personalized adjuvant therapies have been prescribed based on features that predict response to specific types of treatment. In... 
Hematology, Oncology and Palliative Medicine | Primary Breast Cancer | St. Gallen Breast Cancer Consensus | Breast Cancer: Optimal Primary Therapy | Breast Cancer Treatment Guidelines | Chemotherapy | Postmenopausal women | Tamoxifen | Steroid hormones | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
by Conforti, Fabio and Pala, Laura and Bagnardi, Vincenzo and De Pas, Tommaso and Martinetti, Marco and Viale, Giuseppe and Gelber, Richard D and Goldhirsch, Aron
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 737 - 746
Despite the acknowledged sex-related dimorphism in immune system response, little is known about the effect of patients' sex on the efficacy of immune... 
CELL LUNG-CANCER | PHASE-III TRIAL | CHECKPOINT INHIBITORS | ONCOLOGY | ADVANCED MELANOMA | DOUBLE-BLIND | GENDER | NIVOLUMAB | T-CELLS | IPILIMUMAB | CHEMOTHERAPY | Cancer patients | Care and treatment | Analysis | Immunotherapy | Metastasis | Drug therapy | Lung cancer, Non-small cell | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
by Bernhard, Jürg, Dr and Luo, Weixiu, MD and Ribi, Karin, PhD and Colleoni, Marco, MD and Burstein, Harold J, MD and Tondini, Carlo, MD and Pinotti, Graziella, MD and Spazzapan, Simon, MD and Ruhstaller, Thomas, MD and Puglisi, Fabio, MD and Pavesi, Lorenzo, MD and Parmar, Vani, MBBS and Regan, Meredith M, ScD and Pagani, Olivia, MD and Fleming, Gini F, MD and Francis, Prudence A, MD and Price, Karen N, BS and Coates, Alan S, MD and Gelber, Richard D, PhD and Goldhirsch, Aron, MD and Walley, Barbara A, MD
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 848 - 858
Summary Background The combined efficacy analysis of the TEXT and SOFT trials showed a significant disease-free survival benefit with exemestane plus ovarian... 
Hematology, Oncology and Palliative Medicine | IMPACT | ONCOLOGY | INDICATORS | CLINICAL-TRIALS | PREVENTION | ENDOCRINE THERAPY | SYMPTOMS | QUALITY-OF-LIFE | WORTHWHILE | POSTMENOPAUSAL WOMEN | ARIMIDEX | Follow-Up Studies | Humans | Middle Aged | Dose-Response Relationship, Drug | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Ovary - drug effects | Chemotherapy, Adjuvant | Drug Administration Schedule | Risk Assessment | Administration, Oral | Early Detection of Cancer | Self Report | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Tamoxifen - therapeutic use | Premenopause - physiology | Survival Analysis | Quality of Life | Breast Neoplasms - mortality | Tamoxifen - adverse effects | Neoplasm Staging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Why do women opt for contralateral prophylactic mastectomy?
by Goldhirsch, Aron and Gelber, Shari
Nature Reviews Clinical Oncology, ISSN 1759-4774, 08/2014, Volume 11, Issue 8, p. 443
Care and treatment | Patient outcomes | Mastectomy | Breast cancer | Research | Health aspects | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
by Francis, Prudence A and Regan, Meredith M and Fleming, Gini F and Láng, István and Ciruelos, Eva and Bellet, Meritxell and Bonnefoi, Hervé R and Climent, Miguel A and Da Prada, Gian Antonio and Burstein, Harold J and Martino, Silvana and Davidson, Nancy E and Geyer, Charles E and Walley, Barbara A and Coleman, Robert and Kerbrat, Pierre and Buchholz, Stefan and Ingle, James N and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Colleoni, Marco and Viale, Giuseppe and Coates, Alan S and Goldhirsch, Aron and Gelber, Richard D and Int Breast Canc Study Grp and SOFT Investigators and International Breast Cancer Study Group
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
This trial did not support routine use of ovarian suppression in premenopausal breast cancer. Nevertheless, there may be some benefit from ovarian suppression... 
AMENORRHEA | MEDICINE, GENERAL & INTERNAL | THERAPY | YOUNG-WOMEN | CHEMOTHERAPY | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogen | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights